- Home
- FLC vs CHRS Comparison
FLC vs CHRS Comparison
Compare FLC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- CHRS
- Stock Information
- Founded
- FLC 2003
- CHRS 2010
- Country
- FLC United States
- CHRS United States
- Employees
- FLC N/A
- CHRS N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLC Finance
- CHRS Health Care
- Exchange
- FLC Nasdaq
- CHRS Nasdaq
- Market Cap
- FLC 174.2M
- CHRS 84.2M
- IPO Year
- FLC N/A
- CHRS 2014
- Fundamental
- Price
- FLC $17.17
- CHRS $0.90
- Analyst Decision
- FLC
- CHRS Buy
- Analyst Count
- FLC 0
- CHRS 3
- Target Price
- FLC N/A
- CHRS $4.68
- AVG Volume (30 Days)
- FLC 37.8K
- CHRS 1.2M
- Earning Date
- FLC 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- FLC 6.64%
- CHRS N/A
- EPS Growth
- FLC N/A
- CHRS N/A
- EPS
- FLC N/A
- CHRS N/A
- Revenue
- FLC N/A
- CHRS $272,251,000.00
- Revenue This Year
- FLC N/A
- CHRS N/A
- Revenue Next Year
- FLC N/A
- CHRS $106.56
- P/E Ratio
- FLC N/A
- CHRS N/A
- Revenue Growth
- FLC N/A
- CHRS 19.87
- 52 Week Low
- FLC $12.62
- CHRS $0.66
- 52 Week High
- FLC $15.45
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FLC 68.17
- CHRS 59.04
- Support Level
- FLC $16.86
- CHRS $0.73
- Resistance Level
- FLC $17.12
- CHRS $0.82
- Average True Range (ATR)
- FLC 0.12
- CHRS 0.04
- MACD
- FLC 0.01
- CHRS 0.02
- Stochastic Oscillator
- FLC 100.00
- CHRS 88.02
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.